CLLS

Cellectis S.A.

Price Chart

Latest Quote

$2.98

-0.11 (-3.56%)

Current Price

Previous Close	$3.09
Open	$3.07
Day High	$3.15
Day Low	$2.88
Volume	163,492

Fetched: 2026-06-20T02:43:24

Stock Information

Shares Outstanding	72.61M
Total Debt	$82.33M
Cash Equivalents	$185.42M
Revenue	$75.11M
Net Income	$-67.23M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$299.82M
EPS (TTM)	$-0.67
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$118.35M
Sales	$75.11M
Income	$-67.23M
Book/sh	$0.82
Cash/sh	$2.55
Employees	224

Financial Ratios

Quick Ratio	1.49
Current Ratio	1.52
Debt/Eq	137.41

Returns & Margins

ROA	-8.43%
ROE	-76.34%
Gross Margin	100.00%
Operating Margin	-333.43%
Profit Margin	-89.51%

Ownership

Institutional Ownership	16.54%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-4.81
P/S	3.99
P/B	3.61

Analyst Data

Recommendation	buy
Target Price	$7.60

Technical Indicators

SMA20	$3.26
SMA50	$3.66
SMA200	$3.81
RSI	28.57
ATR	0.1859

Shares Float	46.69M
Short Float	0.64%
Short Ratio	12.30
Volatility	2.75
Rel Volume	3.03

Performance History

Week	-3.56%
Month	-17.91%
Quarter	-14.37%
6 Months	-26.60%
YTD	-37.92%
Year	+117.52%
3 Years	+49.00%
5 Years	-80.37%
10 Years	-89.27%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$2.98	163,500
2026-06-17	$3.08	4,400
2026-06-16	$3.05	9,500
2026-06-15	$3.11	10,000
2026-06-12	$3.09	36,700
2026-06-11	$3.09	74,700
2026-06-10	$3.18	109,300
2026-06-09	$2.99	41,900
2026-06-08	$2.93	53,300
2026-06-05	$3.06	47,000
2026-06-04	$3.15	102,000
2026-06-03	$3.09	101,200
2026-06-02	$3.38	46,900
2026-06-01	$3.48	40,000
2026-05-29	$3.52	53,500
2026-05-28	$3.63	86,600
2026-05-27	$3.63	29,100
2026-05-26	$3.67	22,500
2026-05-22	$3.50	13,500
2026-05-21	$3.52	34,500
2026-05-20	$3.66	40,300
2026-05-19	$3.63	52,300

About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

📰 Latest News

European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading

MT Newswires • 2026-06-18T15:06:04Z

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading

MT Newswires • 2026-06-16T15:08:44Z

Ferretti Leads The Charge In European Penny Stock Opportunities

Simply Wall St. • 2026-06-12T06:05:01Z

Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients

MT Newswires • 2026-06-11T15:57:11Z

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading

MT Newswires • 2026-06-10T15:07:47Z

CLLS Stock Rallies Over 24% After Hours — Here's Why

Stocktwits • 2026-06-09T22:30:54Z

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

MT Newswires • 2026-06-09T15:11:39Z

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires • 2026-06-08T15:10:25Z

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week

MT Newswires • 2026-06-05T15:06:40Z

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires • 2026-06-04T15:08:32Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$9,797,000	$9,182,000	$7,419,000	$8,484,000
Cost Of Revenue	$9,797,000	$9,182,000	$7,419,000	$8,484,000
Total Revenue	$72,949,000	$41,506,000	$755,000	$19,171,000
Operating Revenue	$72,949,000	$41,506,000	$755,000	$19,171,000
Expenses
Interest Expense	$8,107,000	$7,453,000	$5,307,000	$3,787,000
Total Expenses	$106,025,000	$101,060,000	$98,058,000	$108,837,000
Other Income Expense	$-36,331,000	$18,968,000	$-16,352,000	$6,060,000
Net Non Operating Interest Income Expense	$1,391,000	$3,825,000	$-2,812,000	$-14,994,000
Interest Expense Non Operating	$8,107,000	$7,453,000	$5,307,000	$3,787,000
Operating Expense	$96,228,000	$91,878,000	$90,639,000	$100,353,000
Other Operating Expenses	$-7,282,000	$-8,561,000	$-7,138,000	$-7,930,000
General And Administrative Expense	$8,596,000	$8,420,000	$8,119,000	$8,895,000
Total Other Finance Cost	-	-	$1,119,000	$12,327,000
Selling And Marketing Expense	-	-	-	$3,108,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-67,593,000	$-36,761,000	$-109,451,000	$-90,794,000
Net Interest Income	$1,391,000	$3,825,000	$-2,812,000	$-14,994,000
Interest Income	$9,498,000	$11,278,000	$3,614,000	$1,120,000
Normalized Income	$-31,487,252	$-55,729,000	$-97,187,000	$-95,339,000
Net Income From Continuing And Discontinued Operation	$-67,593,000	$-36,761,000	$-101,059,000	$-106,139,000
Total Operating Income As Reported	$-33,076,000	$-59,554,000	$-97,302,000	$-89,666,000
Net Income Common Stockholders	$-67,593,000	$-36,761,000	$-101,059,000	$-106,139,000
Net Income	$-67,593,000	$-36,761,000	$-101,059,000	$-106,139,000
Net Income Including Noncontrolling Interests	$-67,593,000	$-36,761,000	$-108,443,000	$-114,034,000
Net Income Discontinuous Operations	$0	$0	$8,392,000	$-15,345,000
Net Income Continuous Operations	$-67,593,000	$-36,761,000	$-116,835,000	$-98,688,000
Pretax Income	$-68,016,000	$-36,761,000	$-116,467,000	$-98,600,000
Interest Income Non Operating	$9,498,000	$11,278,000	$3,614,000	$1,120,000
Operating Income	$-33,076,000	$-59,554,000	$-97,303,000	$-89,666,000
Depreciation Amortization Depletion Income Statement	$1,397,000	$1,483,000	$2,012,000	$1,887,000
Depreciation And Amortization In Income Statement	$1,397,000	$1,483,000	$2,012,000	$1,887,000
Gross Profit	$63,152,000	$32,324,000	$-6,664,000	$10,687,000
Per Share
Diluted EPS	$-0.67	$-0.41	$-1.77	$-2.33
Basic EPS	$-0.67	$-0.41	$-1.77	$-2.33
Other
Tax Effect Of Unusual Items	$-225,252	$0	$-4,088,000	$1,515,000
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-3,516,000	$-28,430,000	$-76,285,000	$-82,438,000
Total Unusual Items	$-36,331,000	$18,968,000	$-16,352,000	$6,060,000
Total Unusual Items Excluding Goodwill	$-36,331,000	$18,968,000	$-16,352,000	$6,060,000
Reconciled Depreciation	$20,062,000	$19,846,000	$18,523,000	$18,435,000
EBITDA (Bullshit earnings)	$-39,847,000	$-9,462,000	$-92,637,000	$-76,378,000
EBIT	$-59,909,000	$-29,308,000	$-111,160,000	$-94,813,000
Diluted Average Shares	$100,279,276	$90,566,346	$57,012,815	$45,553,219
Basic Average Shares	$100,279,276	$90,566,346	$57,012,815	$45,553,219
Diluted NI Availto Com Stockholders	$-67,593,000	$-36,761,000	$-101,059,000	$-106,139,000
Minority Interests	$0	$0	$7,384,000	$7,894,000
Tax Provision	$-423,000	$0	$371,000	$87,000
Gain On Sale Of Security	$-36,331,000	$18,968,000	$-16,352,000	$6,060,000
Research And Development	$93,517,000	$90,536,000	$87,646,000	$97,501,000
Selling General And Administration	$8,596,000	$8,420,000	$8,119,000	$8,895,000
Other Gand A	$915,000	$927,000	$738,000	$1,221,000
Salaries And Wages	$7,681,000	$7,493,000	$7,381,000	$7,674,000
Other Taxes	-	-	$-6,582,000	$-6,546,000

Fetched: 2026-06-10

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$75,366,000	$129,918,000	$84,023,000	$117,250,000
Total Assets	$324,720,000	$383,544,000	$334,270,000	$261,216,000
Total Non Current Assets	$88,476,000	$96,476,000	$101,265,000	$117,406,000
Other Non Current Assets	$20,025,000	$11,595,000	$-1,000	-
Non Current Deferred Assets	$382,000	$382,000	-	-
Non Current Deferred Taxes Assets	$382,000	$382,000	-	-
Investmentin Financial Assets	$5,088,000	$7,521,000	$7,853,000	$8,791,000
Financial Assets Designatedas Fair Value Through Profitor Loss Total	$0	$4,556,000	$4,656,000	$4,716,000
Goodwill And Other Intangible Assets	$535,000	$1,115,000	$672,000	$718,000
Other Intangible Assets	$535,000	$1,115,000	$672,000	$718,000
Current Assets	$236,245,000	$287,069,000	$233,006,000	$143,809,000
Other Current Assets	$330,000	$298,000	$345,000	$538,000
Prepaid Assets	$1,934,000	$3,428,000	$5,716,000	$6,233,000
Receivables	$25,318,000	$23,037,000	$23,130,000	$17,574,000
Other Receivables	$89,000	-	-	-
Taxes Receivable	$10,831,000	$16,323,000	$22,561,000	$16,802,000
Accounts Receivable	$14,398,000	$6,714,000	$569,000	$772,000
Allowance For Doubtful Accounts Receivable	$0	$0	$0	$0
Gross Accounts Receivable	$14,398,000	$6,714,000	$569,000	$772,000
Cash Cash Equivalents And Short Term Investments	$208,663,000	$260,306,000	$203,815,000	$97,696,000
Cash And Cash Equivalents	$61,533,000	$143,251,000	$136,708,000	$89,789,000
Cash Equivalents	$15,618,000	$110,336,000	$55,000,000	$24,778,000
Cash Financial	$45,915,000	$32,915,000	$81,708,000	$65,012,000
Assets Held For Sale Current	-	-	$0	$21,768,000
Current Deferred Assets	-	-	-	$538,000
Inventory	-	-	-	$0
Debt
Total Debt	$90,733,000	$91,461,000	$85,056,000	$75,771,000
Long Term Debt And Capital Lease Obligation	$78,942,000	$78,235,000	$71,392,000	$62,927,000
Long Term Debt	$51,217,000	$43,990,000	$28,444,000	$13,569,000
Current Debt And Capital Lease Obligation	$11,791,000	$13,226,000	$13,664,000	$12,844,000
Current Debt	$4,090,000	$4,841,000	$5,162,000	$4,972,000
Other Current Borrowings	$4,090,000	$4,841,000	$5,162,000	$4,972,000
Liabilities
Total Liabilities Net Minority Interest	$248,819,000	$252,511,000	$249,575,000	$135,275,000
Total Non Current Liabilities Net Minority Interest	$103,068,000	$86,242,000	$94,431,000	$72,280,000
Other Non Current Liabilities	$738,000	$882,000	$12,884,000	$6,963,000
Derivative Product Liabilities	$22,059,000	$6,010,000	$7,797,000	$0
Current Liabilities	$145,751,000	$166,269,000	$155,144,000	$62,995,000
Other Current Liabilities	$7,865,000	$12,544,000	$978,000	$15,680,000
Current Deferred Liabilities	$96,803,000	$112,161,000	$110,325,000	$59,000
Payables And Accrued Expenses	$28,123,000	$27,510,000	$28,437,000	$33,935,000
Payables	$17,357,000	$18,680,000	$19,069,000	$24,514,000
Total Tax Payable	$80,000	$16,000	$0	$3,058,000
Accounts Payable	$17,277,000	$18,664,000	$19,069,000	$21,456,000
Non Current Deferred Liabilities	-	$0	$158,000	-
Non Current Deferred Taxes Liabilities	-	$0	$158,000	-
Equity
Common Stock Equity	$75,901,000	$131,033,000	$84,695,000	$117,968,000
Total Equity Gross Minority Interest	$75,901,000	$131,033,000	$84,695,000	$125,941,000
Stockholders Equity	$75,901,000	$131,033,000	$84,695,000	$117,968,000
Gains Losses Not Affecting Retained Earnings	$-33,316,000	$-39,537,000	$-36,690,000	$-28,605,000
Retained Earnings	$-334,131,000	$-329,607,000	$-405,766,000	$-439,504,000
Other Equity Interest	-	-	$1,000	-
Other
Ordinary Shares Number	$100,339,441	$72,093,873	$71,751,201	$45,675,968
Share Issued	$100,339,441	$72,093,873	$71,751,201	$45,675,968
Tangible Book Value	$75,366,000	$129,918,000	$84,023,000	$117,250,000
Invested Capital	$131,208,000	$179,864,000	$118,301,000	$136,509,000
Working Capital	$90,494,000	$120,800,000	$77,862,000	$80,814,000
Capital Lease Obligations	$35,426,000	$42,630,000	$51,450,000	$57,230,000
Total Capitalization	$127,118,000	$175,023,000	$113,139,000	$131,537,000
Foreign Currency Translation Adjustments	$-33,316,000	$-39,537,000	$-36,690,000	$-28,605,000
Additional Paid In Capital	$437,445,000	$494,288,000	$522,785,000	$583,122,000
Capital Stock	$5,903,000	$5,889,000	$4,365,000	$2,955,000
Common Stock	$5,903,000	$5,889,000	$4,365,000	$2,955,000
Employee Benefits	$1,329,000	$1,115,000	$2,200,000	$2,390,000
Non Current Pension And Other Postretirement Benefit Plans	$1,329,000	$1,115,000	$2,200,000	$2,390,000
Long Term Capital Lease Obligation	$27,725,000	$34,245,000	$42,948,000	$49,358,000
Current Deferred Revenue	$96,803,000	$112,161,000	$110,325,000	$59,000
Current Capital Lease Obligation	$7,701,000	$8,385,000	$8,502,000	$7,872,000
Current Provisions	$1,169,000	$828,000	$1,740,000	$477,000
Current Accrued Expenses	$10,766,000	$8,830,000	$9,368,000	$9,421,000
Investments And Advances	$5,088,000	$7,521,000	$7,853,000	$8,791,000
Available For Sale Securities	$5,088,000	$2,965,000	$3,197,000	$4,075,000
Net PPE	$62,446,000	$75,863,000	$92,741,000	$107,897,000
Accumulated Depreciation	$-113,592,000	$-91,381,000	$-75,415,000	$-55,721,000
Gross PPE	$176,038,000	$167,244,000	$168,156,000	$163,618,000
Construction In Progress	$1,363,000	$186,000	$1,271,000	$952,000
Other Properties	$94,838,000	$92,906,000	$91,505,000	$90,589,000
Machinery Furniture Equipment	$5,166,000	$5,100,000	$4,973,000	$4,914,000
Buildings And Improvements	$53,751,000	$50,913,000	$51,863,000	$49,421,000
Land And Improvements	$20,920,000	$18,139,000	$18,544,000	$17,742,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$147,130,000	$117,055,000	$67,107,000	$7,907,000
Minority Interest	-	-	$0	$7,973,000
Long Term Provisions	-	-	$2,200,000	$2,390,000

Fetched: 2026-06-10

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-42,934,000	$19,146,000	$-25,819,000	$-89,885,000
Operating Activities
Operating Cash Flow	$-39,401,000	$22,989,000	$-24,746,000	$-87,444,000
Cash From Discontinued Operating Activities	$0	$0	$-3,644,000	$-18,601,000
Cash Flow From Continuing Operating Activities	$-39,401,000	$22,989,000	$-21,103,000	$-68,843,000
Operating Gains Losses	$340,000	$-287,000	$8,000	$948,000
Investing Activities
Capital Expenditure	$-3,533,000	$-3,843,000	$-1,073,000	$-2,441,000
Investing Cash Flow	$-29,484,000	$-102,808,000	$-15,510,000	$-2,761,000
Cash From Discontinued Investing Activities	$0	$0	$79,000	$-446,000
Cash Flow From Continuing Investing Activities	$-29,484,000	$-102,808,000	$-15,589,000	$-2,315,000
Net Other Investing Changes	$-1,000	$-1,000	$-1,642,000	-
Financing Activities
Issuance Of Capital Stock	$44,000	$82,822,000	$67,936,000	-
Financing Cash Flow	$-16,761,000	$89,113,000	$82,865,000	$1,145,000
Cash From Discontinued Financing Activities	$0	$0	$1,781,000	$8,650,000
Cash Flow From Continuing Financing Activities	$-16,761,000	$89,113,000	$81,084,000	$-7,505,000
Cash Dividends Paid	$0	$0	$0	$0
Net Common Stock Issuance	$44,000	$82,822,000	$67,936,000	$-569,000
Common Stock Issuance	$44,000	$82,822,000	$67,936,000	-
Net Other Financing Charges	-	-	$1,000	-
Repurchase Of Capital Stock	-	-	-	$-569,000
Other
Repayment Of Debt	$-16,193,000	$-16,063,000	$-16,191,000	$-12,354,000
Issuance Of Debt	$0	$23,201,000	$29,671,000	$5,750,000
End Cash Position	$61,533,000	$143,251,000	$136,708,000	$93,216,000
Beginning Cash Position	$143,251,000	$136,708,000	$93,216,000	$185,636,000
Effect Of Exchange Rate Changes	$3,928,000	$-2,752,000	$884,000	$-3,360,000
Changes In Cash	$-85,646,000	$9,295,000	$42,608,000	$-89,060,000
Interest Paid Cff	$-612,000	$-847,000	$-333,000	$-332,000
Net Issuance Payments Of Debt	$-16,193,000	$7,138,000	$13,480,000	$-6,604,000
Net Long Term Debt Issuance	$-16,193,000	$7,138,000	$13,480,000	$-6,604,000
Long Term Debt Payments	$-16,193,000	$-16,063,000	$-16,191,000	$-12,354,000
Long Term Debt Issuance	$0	$23,201,000	$29,671,000	$5,750,000
Net Investment Purchase And Sale	$-25,950,000	$-98,964,000	$-12,874,000	$126,000
Sale Of Investment	$133,827,000	$63,806,000	$489,000	$126,000
Purchase Of Investment	$-159,777,000	$-162,770,000	$-13,363,000	$0
Net Intangibles Purchase And Sale	$-1,173,000	$-1,260,000	$0	$-10,000
Purchase Of Intangibles	$-1,173,000	$-1,260,000	$0	$-10,000
Net PPE Purchase And Sale	$-2,360,000	$-2,583,000	$-1,073,000	$-2,431,000
Purchase Of PPE	$-2,360,000	$-2,583,000	$-1,073,000	$-2,431,000
Taxes Refund Paid	$-5,000	-	-	-
Interest Received Cfo	$8,428,000	$6,558,000	$3,627,000	$1,158,000
Change In Working Capital	$-41,593,000	$53,665,000	$48,858,000	$-5,723,000
Change In Other Working Capital	$-28,883,000	$5,748,000	$59,149,000	$23,000
Change In Payables And Accrued Expense	$-3,259,000	$2,055,000	$-6,305,000	$3,247,000
Change In Payable	$-3,259,000	$2,055,000	$-6,305,000	$3,247,000
Change In Account Payable	$-3,259,000	$2,055,000	$-6,305,000	$3,247,000
Change In Receivables	$-9,451,000	$45,862,000	$-3,986,000	$-8,993,000
Changes In Account Receivables	$-5,020,000	$52,596,000	$2,252,000	$-3,187,000
Other Non Cash Items	$34,939,000	$-20,785,000	$17,761,000	$8,627,000
Stock Based Compensation	$6,110,000	$3,167,000	$5,233,000	$6,043,000
Provisionand Write Offof Assets	$334,000	$-1,875,000	$1,352,000	$270,000
Deferred Tax	$-423,000	$-539,000	$371,000	$87,000
Deferred Income Tax	$-423,000	$-539,000	$371,000	$87,000
Depreciation Amortization Depletion	$20,062,000	$19,846,000	$18,523,000	$18,435,000
Depreciation And Amortization	$20,062,000	$19,846,000	$18,523,000	$18,435,000
Net Foreign Currency Exchange Gain Loss	$339,000	$-308,000	$8,000	$-664,000
Net Income From Continuing Operations	$-67,593,000	$-36,761,000	$-116,835,000	$-98,688,000
Proceeds From Stock Option Exercised	-	-	$0	$0
Change In Inventory	-	-	$0	$0
Common Stock Payments	-	-	-	$-569,000
Interest Paid Cfo	-	-	-	$1,158,000
Sale Of PPE	-	-	-	-
Gain Loss On Sale Of PPE	-	-	-	-

Fetched: 2026-06-10